Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AMLX Stock Summary
Top 10 Correlated ETFs
AMLX
In the News
Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.
Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn.
Amylyx's ALS drug failed a late-stage trial, raising questions about the future of the drug and the company itself.
Amylyx's ALS Drug Fails Trial, Raising Questions About Company's Future
Relyvrio, which is sold under the name Albrioza in Canada, is Amylyx's only product.
Amylyx's ALS drug fails in late-stage confirmatory study
Amylyx Pharmaceuticals said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study.
The Top 3 Biotech Stocks to Buy in March 2024
Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
Investors may want to jump into oversold Russell 2000 stocks. For one, after a rough outing in 2023, smaller-cap stocks are starting to come back strong.
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates
Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.65 per share a year ago.
Get Rich Quick With These 3 Biotech Stocks to Buy Now
I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.
3 small-cap biotechs with potential breakthroughs in 2024
There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.
AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?
AMLX Financial details
AMLX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.03 | 0.01 | 0.01 | 0.38 | 5.66 | |
Net income per share | -0.33 | -0.98 | -1.59 | -3.39 | 0.73 | |
Operating cash flow per share | -0.23 | -0.8 | -1.35 | -3.07 | 0.18 | |
Free cash flow per share | -0.23 | -0.8 | -1.36 | -3.12 | 0.16 | |
Cash per share | 0.07 | 0.28 | 1.74 | 5.93 | 5.52 | |
Book value per share | -0.56 | -1.45 | -2.74 | 5.82 | 6.45 | |
Tangible book value per share | -0.56 | -1.45 | -2.74 | 5.82 | 6.45 | |
Share holders equity per share | -0.56 | -1.45 | -2.74 | 5.82 | 6.45 | |
Interest debt per share | 0.36 | 0.08 | 0 | 0.18 | 0.06 | |
Market cap | 823.13M | 830.34M | 997.75M | 2.16B | 989.69M | |
Enterprise value | 834.97M | 818.89M | 947.56M | 2.11B | 823.73M | |
P/E ratio | -55.56 | -18.52 | -11.35 | -10.9 | 20.09 | |
Price to sales ratio | 577.23 | 1.28K | 3.5K | 97.23 | 2.6 | |
POCF ratio | -77.02 | -22.63 | -13.34 | -12.02 | 83.03 | |
PFCF ratio | -77.02 | -22.53 | -13.28 | -11.85 | 92.69 | |
P/B Ratio | -32.46 | -12.44 | -6.6 | 6.35 | 2.28 | |
PTB ratio | -32.46 | -12.44 | -6.6 | 6.35 | 2.28 | |
EV to sales | 585.53 | 1.26K | 3.32K | 94.7 | 2.16 | |
Enterprise value over EBITDA | -62.41 | -21.15 | -11.46 | -10.46 | 20.65 | |
EV to operating cash flow | -78.13 | -22.31 | -12.67 | -11.7 | 69.11 | |
EV to free cash flow | -78.13 | -22.22 | -12.61 | -11.54 | 77.14 | |
Earnings yield | -0.02 | -0.05 | -0.09 | -0.09 | 0.05 | |
Free cash flow yield | -0.01 | -0.04 | -0.08 | -0.08 | 0.01 | |
Debt to equity | -0.59 | -0.02 | 0 | 0.02 | 0.01 | |
Debt to assets | 4.64 | 0.1 | 0 | 0.02 | 0.01 | |
Net debt to EBITDA | -0.88 | 0.3 | 0.61 | 0.28 | -4.16 | |
Current ratio | 0.71 | 1.86 | 5.84 | 8.2 | 5.66 | |
Interest coverage | -10.62 | -17.05 | 0 | -46.92 | 0 | |
Income quality | 0.78 | 0.87 | 0.85 | 0.91 | 0.24 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.16 | 23.17 | 136.61 | 5.72 | 0 | |
Research and developement to revenue | 8.34 | 37.84 | 154.53 | 4.2 | 0.34 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.01 | -0.1 | |
Capex to revenue | 0 | -0.23 | -1.24 | -0.11 | 0 | |
Capex to depreciation | 0 | -151 | -6.79 | -5.19 | -1.14 | |
Stock based compensation to revenue | 0.08 | 0.37 | 11 | 0.98 | 0.1 | |
Graham number | 2.02 | 5.65 | 9.9 | 21.08 | 10.31 | |
ROIC | 1.4 | 0.63 | 0.55 | -0.57 | 0.08 | |
Return on tangible assets | -4.6 | -3.18 | -0.83 | -0.51 | 0.1 | |
Graham Net | -0.56 | -1.48 | -2.91 | 5.34 | 5.01 | |
Working capital | -1.33M | 6.31M | 84.11M | 335.52M | 382.62M | |
Tangible asset value | -25.36M | -66.73M | -151.17M | 340.61M | 433.43M | |
Net current asset value | -25.38M | -67.19M | -155.27M | 331.29M | 380.64M | |
Invested capital | -0.59 | -0.02 | 0 | 0.02 | 0.01 | |
Average receivables | 0 | 0 | 0 | 7.65M | 27.68M | |
Average payables | 0 | 2.9M | 10.5M | 32M | 34.34M | |
Average inventory | 0 | 0 | 0 | 4.88M | 24.05M | |
Days sales outstanding | 0 | 0 | 0 | 251.31 | 38.39 | |
Days payables outstanding | 67.33 | 53.62 | 122.11K | 5.68K | 316.51 | |
Days of inventory on hand | 0 | 0 | 0 | 1.19K | 549.82 | |
Receivables turnover | 0 | 0 | 0 | 1.45 | 9.51 | |
Payables turnover | 5.42 | 6.81 | 0 | 0.06 | 1.15 | |
Inventory turnover | 0 | 0 | 0 | 0.31 | 0.66 | |
ROE | 0.58 | 0.67 | 0.58 | -0.58 | 0.11 | |
Capex per share | 0 | 0 | -0.01 | -0.04 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.33 | 1.01 | 1.46 | 1.52 | 1.61 | |
Net income per share | -0.65 | 0.02 | 0.33 | 0.31 | 0.07 | |
Operating cash flow per share | -0.76 | -0.07 | 0.13 | -0.08 | 0.2 | |
Free cash flow per share | -0.77 | -0.08 | 0.12 | -0.08 | 0.2 | |
Cash per share | 5.3 | 4.88 | 5.31 | 5.27 | 5.51 | |
Book value per share | 5.21 | 4.98 | 5.75 | 6.21 | 6.43 | |
Tangible book value per share | 5.21 | 4.98 | 5.75 | 6.21 | 6.43 | |
Share holders equity per share | 5.21 | 4.98 | 5.75 | 6.21 | 6.43 | |
Interest debt per share | 0.14 | 0.03 | 0.08 | 0.07 | 0.06 | |
Market cap | 2.42B | 2.08B | 1.45B | 1.23B | 992.34M | |
Enterprise value | 2.36B | 1.97B | 1.21B | 1.1B | 826.38M | |
P/E ratio | -14.15 | 330.44 | 16.42 | 14.77 | 52.44 | |
Price to sales ratio | 110.45 | 29.11 | 14.77 | 12.02 | 9.15 | |
POCF ratio | -48.64 | -409.93 | 168.46 | -238.8 | 73.23 | |
PFCF ratio | -48.04 | -390.67 | 174.08 | -223.37 | 75.21 | |
P/B Ratio | 7.1 | 5.9 | 3.75 | 2.95 | 2.29 | |
PTB ratio | 7.1 | 5.9 | 3.75 | 2.95 | 2.29 | |
EV to sales | 107.88 | 27.59 | 12.3 | 10.75 | 7.62 | |
Enterprise value over EBITDA | -52.94 | -959.75 | 58.97 | 58.03 | 369.74 | |
EV to operating cash flow | -47.51 | -388.48 | 140.29 | -213.56 | 60.98 | |
EV to free cash flow | -46.92 | -370.23 | 144.97 | -199.76 | 62.63 | |
Earnings yield | -0.02 | 0 | 0.02 | 0.02 | 0 | |
Free cash flow yield | -0.02 | 0 | 0.01 | 0 | 0.01 | |
Debt to equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 1.26 | 52.98 | -11.84 | -6.86 | -74.26 | |
Current ratio | 8.2 | 7.86 | 6.67 | 9.52 | 5.66 | |
Interest coverage | -14.13 | 0.59 | 0 | 0 | 0 | |
Income quality | 1.16 | -3.22 | 0.39 | -0.25 | 2.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.57 | 0.62 | 0.44 | 0.47 | 0 | |
Research and developement to revenue | 1.04 | 0.34 | 0.3 | 0.29 | 0.41 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.05 | -0.03 | 0.07 | -0.03 | |
Capex to revenue | -0.03 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -3.41 | -1.23 | -0.99 | -1.18 | -1.18 | |
Stock based compensation to revenue | 0.28 | 0.11 | 0.1 | 0.1 | 0.09 | |
Graham number | 8.75 | 1.58 | 6.52 | 6.58 | 3.19 | |
ROIC | -0.13 | -0.01 | 0.05 | 0.04 | 0 | |
Return on tangible assets | -0.11 | 0 | 0.05 | 0.04 | 0.01 | |
Graham Net | 4.78 | 4.38 | 4.88 | 5.12 | 4.99 | |
Working capital | 335.52M | 339.53M | 363.31M | 388.49M | 382.62M | |
Tangible asset value | 340.61M | 352.65M | 386.37M | 418.4M | 433.43M | |
Net current asset value | 331.29M | 333.74M | 360.17M | 385.93M | 380.64M | |
Invested capital | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
Average receivables | 7.72M | 16.58M | 26.06M | 31.86M | 34.75M | |
Average payables | 26.83M | 28.69M | 17.73M | 15.53M | 14.22M | |
Average inventory | 5.17M | 11.42M | 18.97M | 28.62M | 35.35M | |
Days sales outstanding | 62.94 | 22.5 | 31.41 | 25.81 | 33.24 | |
Days payables outstanding | 1.49K | 183.48 | 398.31 | 109.89 | 212.13 | |
Days of inventory on hand | 311.67 | 222.74 | 400.94 | 558.39 | 368.49 | |
Receivables turnover | 1.43 | 4 | 2.87 | 3.49 | 2.71 | |
Payables turnover | 0.06 | 0.49 | 0.23 | 0.82 | 0.42 | |
Inventory turnover | 0.29 | 0.4 | 0.22 | 0.16 | 0.24 | |
ROE | -0.13 | 0 | 0.06 | 0.05 | 0.01 | |
Capex per share | -0.01 | 0 | 0 | -0.01 | -0.01 |
AMLX Frequently Asked Questions
What is Amylyx Pharmaceuticals, Inc. stock symbol ?
Amylyx Pharmaceuticals, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol AMLX
What is Amylyx Pharmaceuticals, Inc. stock quote today ?
Amylyx Pharmaceuticals, Inc. stock price is $2.84 today.
Is Amylyx Pharmaceuticals, Inc. stock public?
Yes, Amylyx Pharmaceuticals, Inc. is a publicly traded company.